Acinetobacter baumannii infections in a surgical intensive care unit: Predictors of multi-drug resistance

World Journal of Surgery

Volumn 32, Issue 6, 2008, Pages 1194-1202

  Katsaragakis, Stilianos ^a   Markogiannakis, Haridimos ^a,b   Toutouzas, Konstantinos G ^a   Drimousis, Panagiotis ^a   Larentzakis, Andreas ^a   Theodoraki, Eleni Maria ^a   Theodorou, Dimitrios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NETILMICIN; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN;

ABDOMINAL INJURY; ACINETOBACTER BAUMANNII; ACUTE HEMORRHAGIC PANCREATITIS; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SENSITIVITY; FEMALE; HEART FAILURE; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; KIDNEY FAILURE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PERITONITIS; RESPIRATORY FAILURE; RISK FACTOR; SEPTIC SHOCK; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 43949088799     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-008-9571-3     Document Type: Article

References (39)

1. Vincent JL, Bihari DJ, Suter PM et al (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274:639-644
2. Erbay H, Yalcin AN, Serin S et al (2003) Nosocomial infections in intensive care unit in a Turkish university hospital: a 2-year survey. Intensive Care Med 29:1482-1488
3. Fridkin SK, Steward CD, Edwards JR et al (1999) Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 29:245-252
4. Van Looveren M, Goossens H, ARPAC Steering Group (2004) Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 10:684-704
5. Gomez J, Simarro E, Banos V et al (1999) Six-year prospective study of risk and prognostic factors in patients with nosocomial sepsis caused by Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 18:358-361
6. Corbella X, Montero A, Pujol M et al (2000) Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 38:4086-4095
7. Aloush V, Navon-Venezia S, Seigman-Igra Y et al (2006) Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50:43-48
8. Seifert H, Strate A, Pulverer G (1995) Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 74:340-349
9. Cisneros JM, Rodriguez-Bano J (2002) Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect 8:687-693
10. Villari P, Iacuzio L, Vozzella EA et al (1999) Unusual genetic heterogeneity of Acinetobacter baumannii isolates in a university hospital in Italy. Am J Infect Control 27:247-253
11. Abbo A, Navon-Venezia S, Hammer-Muntz O et al (2005) Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 11:22-29
12. Cisneros JM, Rodriguez-Bano J, Fernandez-Cuenca F et al (2005) Risk factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin Microbiol Infect 11:874-879
13. Reina R, Estenssoro E, Saenz G et al (2005) Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 31:1058-1065
14. Rodriguez-Bano J, Cisneros JM, Fernandez-Cuenca F et al (2004) Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol 25:819-824
15. Cisneros JM, Reyes MJ, Pachón J et al (1996) Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 22:1026-1032
16. Bergogne-Bérézin E, Towner KJ (1996) Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9:148-165
17. Garner JS, Jarvis WR, Emori TG et al (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16:128-140
18. Horan TC, Gaynes RP, Martone WJ et al (1992) CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Am J Infect Control 20:271-274
19. Calandra T, Cohen J (2005) International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med 33:1538-1548
20. National Committee for Clinical Laboratory Standards (2002) Performance standards for antimicrobial susceptibility testing; 11th informational supplement. National Committee for Clinical Laboratory Standards. Pennsylvania, Wayne 22:M100-S12
21. Knaus WA, Draper EA, Wagner DP et al (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818-829
22. Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707-710
23. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864-874
24. Levy MM, Fink MP, Marshall JC et al (2003) SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31:1250-1256
25. Meric M, Willke A, Caglayan C et al (2005) Intensive care unit-acquired infections: incidence, risk factors and associated mortality in a Turkish university hospital. Jpn J Infect Dis 58:297-302
26. Rello J (1999) Acinetobacter baumannii infections in the ICU: customization is the key. Chest 115:1226-1229
27. Li J, Nation RL, Milne RW et al (2005) Evaluation of colistin as an agent against mutli-resistant Gram-negative bacteria. Int J Antimicrob Agents 25:11-25
28. del Mar Tomas M, Cartelle M, Pertega S et al (2005) Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 11:540-546
29. Manikal VM, Landman D, Saurina G et al (2000) Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 31:101-106
30. Lortholary O, Fagon JY, Hoi AB et al (1995) Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis 20:790-796
31. Lee SO, Kim NJ, Choi SH et al (2004) Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 48:224-228
32. Baraibar J, Correa H, Mariscal D et al (1997) Risk factors for infection by Acinetobacter baumannii in intubated patients with nosocomial pneumonia. Chest 112:1050-1054
33. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E et al (2005) Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 31:649-655
34. Go ES, Urban C, Burns J et al (1994) Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344:1329-1332
35. Michalopoulos AS, Tsiodras S, Rellos K et al (2005) Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11:115-121
36. Levin AS, Mendes CM, Sinto SI et al (1996) An outbreak of multiresistant Acinetobacter baumanii in a university hospital in Sao Paulo, Brazil. Infect Control Hosp Epidemiol 17:366-368
37. Koeleman JG, van der Bijl MW, Stoof J et al (2001) Antibiotic resistance is a major risk factor for epidemic behavior of Acinetobacter baumannii. Infect Control Hosp Epidemiol 22:284-288
38. Koeleman JG, Parlevliet GA, Dijkshoorn L et al (1997) Nosocomial outbreak of multi-resistant Acinetobacter baumannii on a surgical ward: epidemiology and risk factors for acquisition. J Hosp Infect 37:113-123
39. Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J et al (2001) Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 33:939-946